CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 160 filers reported holding CRISPR THERAPEUTICS AG in Q4 2018. The put-call ratio across all filers is 1.91 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $609,000 | +48.5% | 10,000 | 0.0% | 0.41% | +31.4% |
| Q3 2019 | $410,000 | -13.0% | 10,000 | 0.0% | 0.32% | -2.8% |
| Q2 2019 | $471,000 | +31.9% | 10,000 | 0.0% | 0.32% | +27.1% |
| Q1 2019 | $357,000 | +24.8% | 10,000 | 0.0% | 0.26% | +0.4% |
| Q4 2018 | $286,000 | -35.6% | 10,000 | 0.0% | 0.25% | -12.4% |
| Q3 2018 | $444,000 | -24.5% | 10,000 | 0.0% | 0.29% | -30.5% |
| Q2 2018 | $588,000 | +28.7% | 10,000 | 0.0% | 0.42% | +20.2% |
| Q1 2018 | $457,000 | -35.1% | 10,000 | -66.7% | 0.35% | -37.4% |
| Q4 2017 | $704,000 | – | 30,000 | – | 0.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |